ArticleInternational journal of molecular sciences2022
Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis.Biomolecules · 2023Pooled it
- Identification of Candidate mRNA and miRNA Molecules Associated with Tuberculosis Through Preliminary Analysis and Validation Using Clinical Samples.International journal of molecular sciences · 2026Article
- Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma.Scientific reports · 2026Article
- Deep learning enhances precision diagnosis and treatment of non-small cell lung cancer: future prospects.Translational lung cancer research · 2025Review
- Review
- Three Circulating miRNAs Related to Non-Small-Cell Lung Cancer Progression: An Integrative Analysis of Their Biological Roles.Biology · 2025Article
- Formation of self-assembly aggregates in traditional Chinese medicine decoctions and their application in cancer treatments.RSC advances · 2025Review
- Interleukin-37 in respiratory diseases: molecular mechanisms and immune modulation.Frontiers in immunology · 2025Review
- The Epithelial Cell-Associated Gene PMAIP1 Serves as a Prognostic Biomarker for Lung Adenocarcinoma and Can Regulate the Stemness of Lung Cancer.Stem cells international · 2025Article
- MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation.PeerJ · 2025Article
- Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene.Hereditas · 2024Article
- Identification of ncRNA Biomarkers in Non-Small Cell Lung Cancer to Address Racial Disparities.Cancer research communications · 2024Article
- A Hybrid CNN-Transformer Model for Predicting N Staging and Survival in Non-Small Cell Lung Cancer Patients Based on CT-Scan.Tomography (Ann Arbor, Mich.) · 2024Article
- Article
- Immunotherapy for small cell lung cancer: the current state and future trajectories.Discover oncology · 2024Review
- Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer.Biomedicines · 2024Review
- Next-generation sequencing as a valuable tool for mutational spectrum in advanced-stage NSCLC patients.Medicine and pharmacy reports · 2024Article
- Article
- Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug-Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma.Biomedicines · 2024Article
- Circulating microRNAs in Cancer: A 5-Year Update with a Focus on Breast and Lung Cancers.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Lung cancers are broadly divided into two categories: non-small-cell lung carcinoma (NSCLC), which accounts for 80-85% of all cancer cases, and small-cell lung carcinoma (SCLC), which covers the remaining 10-15%. Recent advances in cancer biology and genomics research have allowed an in-depth characterization of lung cancers that have revealed new therapy targets (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.